US FDA Principal Deputy Commissioner Bumpus Leaving At Year’s End, Creating Leadership Void

Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.

Goodbye with clock
Namandje Bumpus is saying goodbye to the US FDA. (Shutterstock)

US Food and Drug Administration Principal Deputy Commissioner Namandjé Bumpus’ decision to leave by the end of the year means there is no obvious, internal candidate to serve as acting commissioner in January.

More from Policy & Regulation

More from Wellness